Via high-definition transcranial direct current stimulation (HD-tDCS), Researchers are narrowing in on characterizing the right dose of electrical current to treat chronic fibromyalgia pain.
In a study published in the January 2016 issue of the Journal of Pain, lead author, Laura Castillo-Saavedra of Massachusetts General Hospital, Harvard Medical School wrote: “ No neuromodulation technique has been adopted in clinical practice because of limited efficacy, low response rate, or poor tolerability, despite encouraging preliminary results in treating fibromyalgia (FM) pain”.
HD-tDCS is a kind of neuromodulation that uses constant, low current delivered to particular zones of the brain through electrodes situated on the scalp. The ability to achieve cortical changes even after the stimulation is ended is one of the aspects of tDCS.
A visual analog scale (VAS) and measurements of the brain’s response to neurostimulation, that also includes brain network activation pain scores of contact heat-evoked possibilities is utilized by open label dose enhancement study Castilo-Saavedra’s and colleagues to assess pain in 14 people with fibromyalgia for a maximum of six weeks in the phase II.
The mean number of treatments and optimal stimulation to accomplish a clinically meaningful response, defined as a 50% decrease in pain was the primary outcome goal.
Half of the review members accomplished a 50% pain reduction relief having both responders and nonresponders had significant pain reduction, and over time, a huge change in quality of life was seen.
A median of 15 HD-tDCS sessions through the span of three weeks are required for a significant clinical outcome, according to evaluation of Castilo-Saavedra and he also added, “For a pivotal FM neuromodulation clinical trial with individualized treatment, the methodolgy is thus supported.”
Extra information on the clinical study can be found here. The review is not enrolling extra members right now.